
Condit Exhibits BizSpotlight
Condit Exhibits, founded in 1945 by artist Bill Condit, marks their 80th anniversary in 2025. Originally established as Denver's first graphic design firm, Condit has grown into a leading experiential marketing agency, known for its custom tradeshow exhibits, museum displays, corporate environments, and temporary structures. The company expanded its reach with the 2019 acquisition of Exhibit Source, Inc. in Chicago, broadening its Midwest presence and deepening its expertise in key industries such as food and beverage, heavy industries, healthcare, and technology. Throughout its history, Condit has demonstrated resilience and adaptability, navigating economic downturns in 2001 and 2008 by diversifying its offerings and implementing efficient business practices. Under the leadership of longtime CEO Mike McGowan, the company has seamlessly integrated boutique design with large-scale fabrication, fostering a unified workforce and achieving consistent revenue growth. The recent promotion of Jenny Koehn to President underscores Condit's commitment to innovation, sustainable growth, and embracing emerging technologies like AI to enhance efficiency and environmental responsibility. As the events and experiential industry continue to rebound post-pandemic, Condit has remained an active contributor to recovery, supporting organizations like The Exhibitor Advocate, the Future Workforce Initiative, EDPA's Midwest and Northwest chapters, and educational mentorships with local schools and trade programs. Condit's creative excellence and industry leadership have earned numerous accolades, including recognition on EXHIBITOR's Top 40 list, Event Marketer's Fab 50, and multiple honors in the Exhibit Design Awards, Portable Modular Awards, and Best of beMatrix Awards. 'We, along with our clients and colleagues, navigated uncertain and unprecedented times in the past few years,' said President Jenny Koehn. 'We are fortunate to have come out the other side stronger, more adaptable, and ready to face any new challenges and opportunities that come our way!' Heading into their ninth decade as an organization, Condit will keep their core values of collaborative design, high-quality craftsmanship, and responsive customer service at the forefront of their business strategy with an increasing focus on sustainability and future workforce development. McGowan summarized, 'I couldn't be prouder to work alongside this team every day. Condit has a powerful legacy – one that we can all look forward to continuing to build together as we support our customers and give back to both our industry and our community.' Serving many Colorado brands, Condit is proud to call Denver home. Their headquarters, housed in a historic railroad depot and blacksmith shop at the I-70/I-25 corridor, spans about 157,000 square feet. This main facility includes a full manufacturing floor with state-of-the-art machinery and equipment, temperature-controlled warehouses, and front-office space with dedicated internal departments who perform all company offerings, including sales, marketing, design, construction, engineering, storage, customer service, traffic coordination, and accounting. Their showroom is open during business hours for tours and talks with their team.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
Why Riot Platforms, Inc. (RIOT) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Riot Platforms, Inc. (NASDAQ:RIOT) stands against other Friday's best-performing stocks. Riot Platforms saw its share prices rise by 9.57 percent on Friday to close at $9.85 apiece, mirroring Bitcoin's rally, supported by its improved production of the cryptocurrency last month. As of writing, Bitcoin's prices are up by 2.78 percent at $104,434.90 apiece, as traders cheered news of better-than-expected employment data. Meanwhile, Riot Platforms, Inc. (NASDAQ:RIOT) announced earlier this week that it was able to mine 514 Bitcoins last month, or 11 percent higher than the 463 produced in April, and by 139 percent as compared with the 215 Bitcoins in the same month last year. A computer engineer working in a futuristic office, programming algorithms to mine cryptocurrency. The company said the higher Bitcoin production was supported by an increased hash rate of 35.4 EH/s. Bitcoin mining aside, Riot Platforms, Inc. (NASDAQ:RIOT) said it recently acquired 355 acres of land near its Corsicana site, intended for the development of data centers to serve high-performance compute, which typically require larger footprints than bitcoin mining to utilize the same power capacity. 'We will continue to look to strategically add additional land parcels to ensure that our Corsicana site is ideally suited to support designs for data centers that serve the needs of hyperscale and enterprise tenants,' said Riot Platforms, Inc. (NASDAQ:RIOT) CEO Jason Les. Overall, RIOT ranks 8th on our list of Friday's best-performing stocks. While we acknowledge the potential of RIOT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data